Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2901496 | 0.97 | TLR7 (0.95) | TLR7 | |
| SCHEMBL2849235 | 0.97 | TLR7 (1.00) | TLR7 | |
| Phosphoric Acid SCHEMBL2901247 | 0.97 | TLR7 (0.93) | TLR7 | |
| Succinic Acid SCHEMBL2898930 | 0.96 | TLR7 (0.92) | TLR7 | |
| Succinic Acid SCHEMBL2901412 | 0.96 | TLR7 (0.92) | TLR7 | |
| Fumaric Acid SCHEMBL2902017 | 0.95 | TLR7 (0.90) | TLR7 | |
| Fumaric Acid SCHEMBL2902019 | 0.95 | TLR7 (0.90) | TLR7 | |
| SCHEMBL2848225 | 0.95 | TLR7 (1.00) | TLR7 | |
| Pyrophosphoric Acid SCHEMBL2899330 | 0.94 | TLR7 (0.89) | TLR7 | |
| Benzoic Acid SCHEMBL2901421 | 0.94 | TLR7 (0.88) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435412-B1 | SACCHARIN, FUMARIC ACID, 1-HYDROXY-2-NAPHTHOIC ACID AND BENZOIC ACID SALTS OF 4-(DIMETHYLAMINO)BUTYL 2-(4-((2-AMINO-4-METHYL-6-(PENTYLAMINO)PYRIMIDIN-5-YL)METHYL)PHENYL)ACETATE | ASTRAZENECA AB (SE) | 2016-01-27 | — | — | EP | claimed |
| US-8765939-B2 | Pyrimidline derivatives having immune modulating properties that act via TLR7 for the treatment of viral or allergic diseases and cancers | ASTRAZENECA AB (SE) | 2014-07-01 | — | — | US | claimed |
| US-8476288-B2 | Salts 756 | ASTRAZENECA AB (SE) | 2013-07-02 | — | — | US | claimed |
| US-20130045955-A1 | NOVEL COMPOUNDS | BENNETT NICHOLAS J (GB) | 2013-02-21 | — | — | US | claimed |
| EP-2222648-B1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ASTHMA, COPD, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS, ATOPIC DERMATITIS, CANCER, HEPATITIS B, HEPATITIS C, HIV, HPV, BACTERIAL INFECTIONS AND DERMATOSIS | ASTRAZENECA AB (SE) | 2013-01-09 | — | — | EP | claimed |
| US-8268990-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-09-18 | — | — | US | claimed |
| WO-2010133882-A1 | DISACCHARIN, DIFUMARIC ACID, DI-L-HYDROXY-2-NAPHTHOIC ACID AND MONO-BENZOIC ACID SALTS OF 4- (DIMETHYLAMIN0)BUTYL 2- (4- ( (2-AMINO-4-METHYL-6- (PENTYLAMINO) PYRIMIDIN- 5 -YL) METHYL) PHENYL)ACETATE | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | WO | claimed |
| US-20100298364-A1 | SALTS 756 | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | claimed |
| EP-2222648-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ASTHMA, COPD, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS, ATOPIC DERMATITIS, CANCER, HEPATITIS B, HEPATITIS C, HIV, HPV, BACTERIAL INFECTIONS AND DERMATOSIS | AstraZeneca AB (SE) | 2010-09-01 | — | — | EP | claimed |
| US-20090209524-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-08-20 | — | — | US | claimed |
| WO-2009067081-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ASTHMA, COPD, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS, ATOPIC DERMATITIS, CANCER, HEPATITIS B, HEPATITIS C, HIV, HPV, BACTERIAL INFECTIONS AND DERMATOSIS | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | WO | claimed |
| US-10954211-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2021-03-23 | — | — | US | disclosed |
| CN-106103423-B | Pyrazine compounds | 阿斯利康(瑞典)有限公司 | 2019-12-06 | — | — | CN | disclosed |
| US-20190330187-A1 | Chemical Compounds | ASTRAZENECA UK LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| US-10336725-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2019-07-02 | — | — | US | disclosed |
| US-20090209524-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-08-20 | — | — | US | disclosed |
| US-20090209524-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-08-20 | — | — | US | disclosed |
| US-20090209524-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-08-20 | — | — | US | disclosed |
| WO-2009067081-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ASTHMA, COPD, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS, ATOPIC DERMATITIS, CANCER, HEPATITIS B, HEPATITIS C, HIV, HPV, BACTERIAL INFECTIONS AND DERMATOSIS | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009067081-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ASTHMA, COPD, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS, ATOPIC DERMATITIS, CANCER, HEPATITIS B, HEPATITIS C, HIV, HPV, BACTERIAL INFECTIONS AND DERMATOSIS | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336725-B2 | Chemical compounds | CFTR, SCNN1B, SCNN1A | TLR7 3230/4885 |
| US-10954211-B2 | Chemical compounds | CFTR, SCNN1B, SCNN1A | TLR7 3230/4885 |
| US-20090209524-A1 | Novel Compounds | ABCG2, CYP4B1, CYP3A4 | TLR7 3271/4885 |
| US-20130045955-A1 | NOVEL COMPOUNDS | ABCG2, F12, CFTR | TLR7 2987/4885 |
| US-20100298364-A1 | SALTS 756 | SLC10A6, SLC10A1, SLC6A6 | TLR7 1895/4885 |
| US-20190330187-A1 | Chemical Compounds | CFTR, SCNN1B, SCNN1A | TLR7 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.